Cell Lung Cancer
Non-Small Cell Lung Cancer II
Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer II
Early-Stage Lung Cancer: Assessment and Treatment
FDA approves Augtyro for treatment of certain patients with non-small cell lung cancer
The FDA approved repotrectinib for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer.
FDA approves Keytruda for adjuvant, neoadjuvant treatment of non-small cell lung cancer
The FDA approved pembrolizumab plus platinum-containing chemotherapy as neoadjuvant therapy, followed by single-agent pembrolizumab as adjuvant therapy after surgery for adults with resectable non-small cell lung cancer.
Rybrevant combination extends PFS in EGFR-mutant non-small cell lung cancer
Amivantamab plus lazertinib improved PFS compared with osimertinib as first-line therapy in adults with locally advanced or metastatic EGFR-mutated non-small cell lung cancer, according to the agent’s manufacturer.
Combination extends survival in extensive-stage small cell lung cancer
The addition of benmelstobart and anlotinib to chemotherapy significantly improved median PFS and OS compared with chemotherapy alone among patients with extensive-stage small cell lung cancer, according to study results.
Severe myelosuppression common after chemotherapy for small cell lung cancer
Nearly all individuals who received chemotherapy for extensive-stage small cell lung cancer experienced a treatment-related myelosuppressive episode, results of a retrospective study published in Cancer Medicine showed.